VRDN-001の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

Viridianの主要製品候補であるVRDN-001は、バセドウ病眼症の治療薬として臨床的、商業的に検証されているインスリン様成長因子1受容体（IGF-1R）を標的とする分化型モノクローナル抗体です。

前臨床試験において、VRDN-001はIGF-1Rの完全な拮抗薬であり、唯一承認されているバセドウ病眼症治療薬を含む他の抗IGF-1R抗体よりも完全に受容体を遮断することが示されました。進行中のフェーズII試験の初回投与コホートから得られたデータは、活動性のバセドウ病眼症患者におけるVRDN-001の臨床的概念実証を確立しました。進行中の臨床試験の予備データでは、VRDN-001の投与により、臨床的に意義のある前突症の軽減、臨床活動性スコア（CAS）の改善、複視の消失が認められました。VRDN-001はこの試験において概して安全であり、忍容性も良好でした。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）におけるバセドウ病眼症向けVRDN-001について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 バセドウ病眼症におけるVRDN-001の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 VRDN-001市場の評価

• バセドウ病眼症におけるVRDN-001の市場見通し
• 主要7市場の分析
  • 主要7市場のバセドウ病眼症向けVRDN-001の市場規模
• 市場の分析：国別
  • 米国のバセドウ病眼症向けVRDN-001の市場規模
  • ドイツのバセドウ病眼症向けVRDN-001の市場規模
  • 英国のバセドウ病眼症向けVRDN-001の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: VRDN-001, Clinical Trial Description, 2023
• Table 2: VRDN-001, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: VRDN-001 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: VRDN-001 Market Size in the US, in USD million (2019-2032)
• Table 7: VRDN-001 Market Size in Germany, in USD million (2019-2032)
• Table 8: VRDN-001 Market Size in France, in USD million (2019-2032)
• Table 9: VRDN-001 Market Size in Italy, in USD million (2019-2032)
• Table 10: VRDN-001 Market Size in Spain, in USD million (2019-2032)
• Table 11: VRDN-001 Market Size in the UK, in USD million (2019-2032)
• Table 12: VRDN-001 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: VRDN-001 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: VRDN-001 Market Size in the United States, USD million (2019-2032)
• Figure 3: VRDN-001 Market Size in Germany, USD million (2019-2032)
• Figure 4: VRDN-001 Market Size in France, USD million (2019-2032)
• Figure 5: VRDN-001 Market Size in Italy, USD million (2019-2032)
• Figure 6: VRDN-001 Market Size in Spain, USD million (2019-2032)
• Figure 7: VRDN-001 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: VRDN-001 Market Size in Japan, USD million (2019-2032)

"VRDN-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VRDN-001 for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the VRDN-001 for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VRDN-001 for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VRDN-001 market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.

Drug Summary:

Viridian's lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves' Ophthalmopathy.

In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves' Ophthalmopathy therapy. Data from the initial dose cohorts of the Phase II portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active Graves' Ophthalmopathy. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to clinically meaningful reductions in proptosis, improvement in clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well-tolerated in the trial.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VRDN-001 description, mechanism of action, dosage and administration, research and development activities in Graves' Ophthalmopathy.
• Elaborated details on VRDN-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VRDN-001 research and development activities in Graves' Ophthalmopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VRDN-001.
• The report contains forecasted sales of VRDN-001 for Graves' Ophthalmopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Graves' Ophthalmopathy.
• The report also features the SWOT analysis with analyst views for VRDN-001 in Graves' Ophthalmopathy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VRDN-001 Analytical Perspective by DelveInsight

• In-depth VRDN-001 Market Assessment

This report provides a detailed market assessment of VRDN-001 for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• VRDN-001 Clinical Assessment

The report provides the clinical trials information of VRDN-001 for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Graves' Ophthalmopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VRDN-001 dominance.
• Other emerging products for Graves' Ophthalmopathy are expected to give tough market competition to VRDN-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VRDN-001 in Graves' Ophthalmopathy.
• Our in-depth analysis of the forecasted sales data of VRDN-001 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VRDN-001 in Graves' Ophthalmopathy.

Key Questions:

• What is the product type, route of administration and mechanism of action of VRDN-001?
• What is the clinical trial status of the study related to VRDN-001 in Graves' Ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VRDN-001 development?
• What are the key designations that have been granted to VRDN-001 for Graves' Ophthalmopathy?
• What is the forecasted market scenario of VRDN-001 for Graves' Ophthalmopathy?
• What are the forecasted sales of VRDN-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VRDN-001 for Graves' Ophthalmopathy?
• Which are the late-stage emerging therapies under development for the treatment of Graves' Ophthalmopathy?

Table of Contents

1. Report Introduction

2. VRDN-001 Overview in Graves' Ophthalmopathy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VRDN-001 Market Assessment

• 5.1. Market Outlook of VRDN-001 in Graves' Ophthalmopathy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VRDN-001 in the 7MM for Graves' Ophthalmopathy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VRDN-001 in the United States for Graves' Ophthalmopathy
  • 5.3.2. Market Size of VRDN-001 in Germany for Graves' Ophthalmopathy
  • 5.3.3. Market Size of VRDN-001 in France for Graves' Ophthalmopathy
  • 5.3.4. Market Size of VRDN-001 in Italy for Graves' Ophthalmopathy
  • 5.3.5. Market Size of VRDN-001 in Spain for Graves' Ophthalmopathy
  • 5.3.6. Market Size of VRDN-001 in the United Kingdom for Graves' Ophthalmopathy
  • 5.3.7. Market Size of VRDN-001 in Japan for Graves' Ophthalmopathy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options